Categories Earnings, LATEST, Technology

Earnings Preview: Cognizant’s revenue to grow 8% in Q3

Cognizant Technology Solutions Corporation (CTSH) is set to report third-quarter 2018 earnings results on Tuesday, October 30, before market opens. Wall Street expects the company to report EPS of $1.13, reflecting a year-over-year growth of 12.9%. Revenue is anticipated to grow 8.3% to $4 billion.

Looking at the past four quarters, Cognizant has consistently surpassed estimates on earnings but on revenue, the company has come shy twice. The firm is seeing good demand for its various solutions such as cloud and analytics.

Cognizant’s strategy of acquiring different companies has proved fruitful as these acquisitions have helped the firm boost its cloud portfolio and digital capabilities as well as acquire a large customer base. The technology giant is also focusing its efforts on increasing its strategic client base. However, Cognizant continues to face numerous headwinds such as competitive pressures in the information technology sector.

In the second quarter, Cognizant surpassed earnings estimates but missed on revenues. Revenues grew 9% to $4 billion while earnings grew 28% to $1.19 per share. The company also saw revenue growth across all segments and regions.

For the third quarter, Cognizant provided an outlook for revenues in the range of $4.06 billion to $4.10 billion and EPS of $1.13. For full-year 2018, the company expects revenues of $16.05 billion to $16.30 billion and earnings of at least $4.50 per share.

Looking at the past three months, Cognizant’s shares are down 13% while over the past one month, the stock is down 6%. The stock was down 1.3% as of 2:50 pm ET on Friday.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top